GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on 7 August 2025, the Company will receive an upfront settlement of $370M. GSK will also receive a 1% royalty in respect of US sales of influenza, COVID-19 and related combination mRNA vaccine products by BioNTech (BNTX) and Pfizer (PFE) from the beginning of 2025. These payments are due to GSK in accordance with the terms of its existing license agreement with CureVac. Of the upfront settlement amount, $320m will be in cash. The remainder is attributed to the value of an amendment to GSK’s existing agreement with CureVac, which includes a significant reduction in royalties to be paid by GSK on our potential future mRNA influenza, COVID-19 and influenza/COVID-19 combination products. If the pending acquisition of CureVac by BioNTech successfully closes, the mRNA patent litigation between CureVac and BioNTech outside of the US will also be settled. GSK would then be entitled to an additional $130 million in cash and 1% royalty payments in respect of future sales outside of the US by BioNTech and Pfizer.